




Topic: Nutrition and cancer



UNIVERSITY OF HELSINKI



Karolinska
Institutet

BIOELECTRICAL IMPEDANCE ANALYSIS FOR THE ASSESSMENT OF BODY COMPOSITION IN ONCOLOGY : A SCOPING REVIEW

M. G. BRANCO ^{1, 2}, C. MATEUS ², P. M. NEVES ^{2, 3}, M. L. CAPELAS ³, N. M. PIMENTA ^{3, 4, 5}, T. SANTOS ^{3, 6}, A. MÄKITIE ^{7, 8, 9}, P. RAVASCO ^{3, 10, 11}

1. Dietetics and Nutrition, Hospital Beatriz Ângelo, Loures, Portugal 2. Institute of Health Sciences, Universidade Católica Portuguesa, Lisbon, Portugal 3. Centre for Interdisciplinary Research in Health (CIIS), Universidade Católica Portuguesa, Lisbon, Portugal 4. Polytechnic Institute of Santarém, Sport Sciences School of Rio Maior, Rio Maior, Portugal 5. Interdisciplinary Centre for the Study of Human Performance, Faculdade de Motricidade Humana, Universidade de Lisboa, Lisbon, Portugal 6. European University, Lisbon, Portugal 7. Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Finland 8. Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland 9. Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden 10. Católica Medical School, Universidade Católica Portuguesa, Sintra, Portugal 11. Centre for Interdisciplinary Research in Health Egas Moniz (CiEM), Almada, Portugal

First author's contact details: marianasgbranco@gmail.com

INTRODUCTION

Bioelectrical Impedance Analysis (BIA) has emerged as a reliable, non-invasive, objective and cost-effective method showing high reproducibility and requiring little training for the equipment to be used ¹. Furthermore, recent studies have suggested potential benefits of BIA and BIA-derived measures for body composition assessment in cancer patients ^{2,3}, thus with clinical relevance.

AIM

This scoping review aims to evaluate the current scientific and clinical evidence for BIA for body composition assessment in patients with cancer, and under active treatment.

METHODS

Literature search was conducted through MEDLINE, CINAHL, Scopus and Web of Science, following PRISMA Guidelines ⁴. Included studies were written in English, conducted in adults, concerning all cancer types, using BIA assessment, and published between 2011 and 2021. Studies in benign pathology or only assessing nutritional status were excluded. Two reviewers independently screened the titles and abstracts of included studies using Rayyan. Conflicts were discussed and resolved between the two reviewers. After full-text screening, study selection was conducted.

CONCLUSIONS

The findings of this scoping review suggest that BIA-derived measures, particularly fat-free mass (FFM), Phase Angle (PA) and Bioelectrical Impedance Vector Analysis (BIVA), have shown a good potential and relevant clinical value in preoperative risk evaluation, postoperative complications and hospital length of stay, and as important prognostic markers in cancer patients. BIA seems to be a valid method for the assessment of body composition and related hazards in oncology.

RESULTS

From the initially retrieved 2070 studies, 51 were eligible and 36 were included in this scoping review: 18 prospective ⁵⁻²², 11 systematic reviews ^{1,3, 23-31}, 6 cross-sectional ³²⁻³⁷ and 1 retrospective ³⁸.

Population size for the included original articles ranged from 18 to 1217 participants, comprising a total of 3015 cancer patients with a mean baseline BMI ranging from 20.3 to 30.0 kg/m² and mean age ranging between 47 and 70 years. Review articles included 273 studies, encompassing 78 350 participants.





Figure 1. Flow diagram of included studies, according to PRISMA 2020 Guidelines.⁴

The 36 studies considered in this review reported patients with head and neck cancer (n=8) ^{5-8, 22, 23, 25, 27}, breast cancer (n=4) ^{14, 28, 33, 37}, esophageal cancer (n=2) ^{9, 29}, liver cancer (n=2) ^{10, 12}, pancreatic cancer (n=2) ^{11, 30}, gastric cancer (n=2) ^{31, 34}, colorectal cancer (n=7) ^{13, 15-18, 21, 38}, lung cancer (n=1) ³⁵, skin cancer (n=1) ³² and multiple cancer types (n=7) ^{1, 3, 19, 20, 24, 26, 36}.



REFERENCES

